Result
| Gene | Variant | Type | Tumor | Drug | Drug level | Reference | More | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SMARCB1 | Oncogenic Mutations | MUT | All Liquid Tumors | Tazemetostat | V | 4 | |||||||
|
Evidence region
OncoKB Patient Criteria- NoteTazemetostat showed a favourable safety profile and antitumour activity in patients with refractory B-cell non-Hodgkin lymphoma and advanced solid tumours, including epithelioid sarcoma. Gene name
Full name
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1 Gene typeprotein-coding FunctionThe protein encoded by this gene is part of a complex that relieves repressive chromatin structures, allowing the transcriptional machinery to access its targets more effectively. The encoded nuclear protein may also bind to and enhance the DNA joining activity of HIV-1 integrase. This gene has been found to be a tumor suppressor, and mutations in it have been associated with malignant rhabdoid tumors. Alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Dec 2015] Drug name
Tazemetostat DrugBank ID SynonymsTazemetostat Tazverik DescriptionTazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.[L11476] Tazemetostat was first named in literature as EPZ-6438.[A190363] Tazemetaostat was granted FDA approval on 23 January 2020.[L11476] Target gene
|
|||||||||||||